Title

Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID

lung disease

Authors

Puja Mehta[2]*, Blanca Sanz-Magallón Duque de Estrada[1]*†, Emma K Denneny[2]*,

Kane Foster[3], Carolin T Turner[1], Andreas Mayer[1], Martina Milighetti[1], Manuela Platé[2],

Kaylee B Worlock[2], Masahiro Yoshida[2], Jeremy S Brown[2], Marko Z Nikolić[2], Benjamin

M Chain[1], Mahdad Noursadeghi[1], Rachel C Chambers[2]*, Joanna C Porter[2]*, Gillian S

Tomlinson[1]*†

*These authors contributed equally.

†Corresponding authors.

Affiliations

1. Division of Infection and Immunity, University College London, London, UK

2. UCL Respiratory, University College London, London, UK

3. UCL Cancer Institute, University College London, London, UK

Corresponding authors

Dr Gillian S Tomlinson and Dr Blanca Sanz-Magallón Duque de Estrada, Infection and

Immunity, University College London, Cruciform Building, Gower Street, London

WC1E 6BT, United Kingdom. Email: g.tomlinson@ucl.ac.uk,

blanca.estrada.16@ucl.ac.uk

ABSTRACT

Background Persistent radiological lung abnormalities are evident in many survivors

of acute coronavirus disease 2019 (COVID-19). Consolidation and ground glass

opacities are interpreted to indicate subacute inflammation whereas reticulation is

thought to reflect fibrosis. We sought to identify differences at molecular and cellular

level, in the local immunopathology of post-COVID inflammation and fibrosis.

Methods We compared single-cell transcriptomic profiles and T cell receptor (TCR)

repertoires of bronchoalveolar cells obtained from convalescent individuals with each

radiological pattern, targeting lung segments affected by the predominant abnormality.

Results Single-cell transcriptomes of inflammatory and fibrotic post-COVID lung

disease closely resembled each other across all cell types. However, CD4 central

memory T cells and CD8 effector memory T cells were significantly more abundant in

those with inflammatory radiology. Clustering of similar TCRs from multiple donors

was a striking feature of both phenotypes, consistent with tissue localised antigen-

specific immune responses. There was no enrichment for known SARS-CoV-2-

reactive TCRs, raising the possibility of T cell-mediated immunopathology driven by

failure in immune self-tolerance.

Conclusions We found no evidence that post-COVID radiographic inflammation and

fibrosis are associated with differential immmunopathological pathways. Both show

evidence of shared antigen-specific T cell responses, suggesting a role for therapies

targeting T cells in limiting post-COVID lung damage.

INTRODUCTION

Persistent functional and radiological lung abnormalities are evident at one year in

approximately 20% of people who survive acute coronavirus disease 2019 (COVID-

19) (Fabbri et al., 2023). Current understanding of the immunopathogenic

mechanisms responsible for post-COVID lung disease (PCLD) is very limited (Mehta

et al., 2022). Elevated numbers of airway CD4 and CD8 T cells have been reported

(Cheon et al., 2021; Vijayakumar et al., 2022) and the post-COVID airway proteome

displays evidence of ongoing epithelial injury that resolves with time (Vijayakumar et

al., 2022). It is imperative to address this knowledge deficit to inform therapeutic

interventions that could expedite resolution of pathology and minimize irreversible

tissue damage, to reduce long term morbidity secondary to PCLD and the attendant

burden on healthcare services.

There has been the impression of two major radiological patterns in PCLD:

consolidation and ground glass opacities, thought to represent subacute inflammation,

and reticulation, widely interpreted as fibrosis (Fabbri et al., 2023; Stewart et al., 2022).

Inflammation predominates during acute COVID-19, but fibrosis is evident on 32% of

computed tomography (CT) scans during hospitalisation. Follow-up imaging within the

first year suggests radiological sequelae reduce with time, with less marked

improvement in fibrosis (Fabbri et al., 2023). We hypothesised that these distinct

radiological changes reflect distinct pathogenic mechanisms, which may require

different treatments. We sought to evaluate the molecular characteristics of cellular

function at the site of disease in PCLD, by single-cell RNA sequencing (scRNAseq) of

bronchoalveolar cells from convalescent individuals infected during the first or second

waves of the pandemic, with predominant CT features of inflammation or fibrosis at

the time of sampling.

We showed that in comparison to fibrotic PCLD, the bronchoalveolar environment of

inflammatory PCLD was enriched for CD4 T central memory cells (TCM) and CD8 T

effector memory cells (TEM). Consistent with this finding, a higher proportion of CD4

TCM clones were expanded in the inflammatory phenotype. Both inflammatory and

fibrotic PCLD bronchoalveolar T cells exhibited high levels of T cell receptor (TCR)

clustering, indicative of an antigen-specific immune response, but there was no

enrichment for known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-

2)-reactive sequences. No major differences were evident in any of the cell type-

specific transcriptomic profiles of the two radiological phenotypes, suggesting that they

may represent different manifestations of the same disease process.

RESULTS

Increased abundance of bronchoalveolar T cells in inflammatory PCLD

Individuals undergoing bronchoscopy for clinical investigation of persistent respiratory

symptoms and predominant radiological features of either inflammation or fibrosis

following acute COVID-19, with no previous evidence of interstitial lung disease (ILD)

were recruited (Figure 1a). Bronchoalveolar lavage (BAL) samples from lung

segments affected by the predominant abnormality were obtained from five subjects

with each radiological pattern (Figure 1a). Clinical and demographic characteristics

are provided in Table 1 and Supplementary Table 1. Evaluation of the composition of

post-COVID BAL by scRNAseq revealed that macrophages dominated in all subjects,

with smaller T cell, NK T cell, dendritic cell, epithelial and B cell populations also

identified (Figure 1b-d and Supplementary Figure 1a-d). Each of the cell types

expressed high levels of independently established marker genes (Adams et al., 2020;

Cheng et al., 2021; David et al., 2021; Davies et al., 2013; Davis and Wypych, 2021;

Gardell and Parker, 2017; Glass et al., 2020; Murray and Wynn, 2011; Tsyklauri et al.,

2023; van Aalderen et al., 2021; Villani et al., 2017), validating our annotations (Figure

1d). The notable difference between the two phenotypes was significantly higher

abundance of CD4 T cells and CD8 T cells in inflammatory PCLD (Figure 1e). The

relative proportions of the other seven cell types present were not found to differ

between the two radiological phenotypes, providing confidence our analysis was not

confounded by compositional bias, where alterations in the proportion of one cell type

lead to many other cell types being falsely identified as differentially abundant.

To explore differences in cell type-specific transcriptional profiles between the two

radiological phenotypes, we first aggregated gene expression count data for each cell

type for each donor to form "pseudobulks". We leveraged the ability of pseudobulk

statistical approaches to account for variability of biological replicates, allowing

detection of genuine differential gene expression whilst minimizing false discoveries

(Squair et al., 2021). Very few cell type-specific differentially expressed genes were

identified (Supplementary Table 2), which precluded further bioinformatic analysis and

suggested the transcriptomes of inflammatory and fibrotic PCLD were similar for all

cell types.

Detection of transcriptomic differences between the two groups using pseudobulk

statistical analysis may have been limited by small sample size. Therefore, we

repeated the comparison of inflammatory and fibrotic PCLD at the level of individual

cells. Single-cell statistical analysis identified thousands of cell type-specific

differentially expressed genes in each radiological phenotype. However, single-cell

differential gene expression analysis has a propensity for false positive results (Squair

et al., 2021). To mitigate against this, we sought to assess whether differentially

expressed gene lists represented differentially enriched biological pathways in the two

study groups. This was not evident at the level of biological processes or upstream

regulator analysis (Supplementary Figure 2 and 3), which suggested enrichment of

overlapping processes and pathways despite apparent differential gene expression.

Hence, our single-cell analysis also supports the outcome of the pseudobulk analysis.

CD4 central memory and CD8 effector memory are the predominant T cell

subsets in PCLD

Given that greater abundance of T cells in inflammatory cases was the only robust

difference between the two PCLD radiological phenotypes, we re-clustered these

populations alone to undertake a more detailed analysis. This revealed CD4 TCM and

CD8 TEM as the two predominant T cell subsets in the PCLD bronchoalveolar

environment, and a smaller population of regulatory T cells (Treg). A small mixed T

cell cluster, which expressed high levels of interferon-stimulated genes and an NK cell

cluster were also present in all samples. A minor population of gamma delta T cells

was identified in one individual with inflammatory PCLD (Figure 2a-c). There was no

difference in the relative proportions of any T cell subset between the two PCLD

phenotypes (Figure 2d).

Analysis of T cell subset pseudobulks revealed no genes as differentially expressed

in either group (Supplementary Table 2), consistent with our earlier observation of few

differences between the transcriptional programmes of the two PCLD phenotypes at

the level of broad cell types defined using the full dataset. In single-cell differential

expression analysis of T cells, genes expressed at a significantly higher level in CD4

TCM and CD8 TEM in inflammatory PCLD exhibited weak enrichment for immune

response signalling pathways (Supplementary Figure 4a). Robust enrichment of

cellular pathways in anti-viral responses was evident for genes expressed at a

significantly higher level in CD4 TCM and CD8 TEM in fibrotic PCLD (Supplementary

Figure 4b), but this was not supported by enrichment for Type I interferon signalling in

upstream regulator analysis (Supplementary Figure 5b). Interestingly, interleukin (IL)2

and IL15 were the most statistically significant upstream regulators of CD4 TCM and

CD8 TEM differentially expressed genes in inflammatory PCLD but not fibrotic PCLD,

consistent with the notion of cytokine driven proliferation leading to increased

abundance of T cells in the former phenotype (Supplementary Figure 5a-c).

Alveolar macrophage and monocyte subsets in PCLD are consistent with

healthy airspace myeloid populations

Macrophages are the most abundant cell types in healthy airspaces (Mould et al.,

2021) and were also found to be the most abundant cell type in PCLD BAL samples

in the present study. Macrophage subpopulations have been implicated in the

pathogenesis of fibrosis associated with severe COVID-19 and idiopathic pulmonary

fibrosis (Nouno et al., 2019; Wendisch et al., 2021). We therefore re-clustered

macrophages alone to further our understanding of macrophage subpopulations in

PCLD. Two populations with similar expression of macrophage markers and

comparable transcriptomic profiles, likely representative of the transcriptional

spectrum of resident healthy alveolar macrophages (AM) (Mould et al., 2021) were

combined for subsequent analysis (Figure 3a,b and Supplementary Figure 6a,b). We

identified three further small specialized AM subsets previously detected in healthy

individuals (Mould et al., 2021), characterized by high levels of proinflammatory

molecule expression, "Inflam AM", metal-binding metallothioneins, "MT-AM", or

interferon-stimulated genes "IFN stim AM". Proliferating macrophages were delineated

by high expression of a gene module representing the cellular proliferation response

(Chandran et al., 2022) (Figure 3a-d).

Monocyte-like cells are present in healthy airspaces, and suggested by trajectory

inference and increasing expression of macrophage marker genes over pseudotime

to differentiate into AM, implying constant trafficking of monocytes into the lung (Mould

et al., 2021). Consistent with this, we identified *CD14, FCN1* expressing classical

monocytes (*FCN1*-Mono) (Mould et al., 2021; Wauters et al., 2021) characterized by

high levels of *CCR2*, the receptor for monocyte chemoattractant protein, suggestive

of recent recruitment from the peripheral blood (Auffray et al., 2009) (Figure 3c,d). A

second *LGMN* and *SPP1* expressing subset (*LGMN*-Mono), recently identified as a

rare population defined by expression of cell-matrix interaction genes in healthy

airspaces (Mould et al., 2021), was also present (Figure 3c,d). In contrast to acute

severe COVID-19 where proinflammatory monocytes and profibrotic *SPP1, LGMN*

expressing macrophages have been reported to be abundant (Liao et al., 2020;

Wendisch et al., 2021), monocytes represented a minor constituent of PCLD BAL.

Neither subset expressed high levels of inflammatory mediators (Figure 3c,d) and very

few cells expressed a gene signature characteristic of profibrotic macrophages

recently identified in idiopathic pulmonary fibrosis (Adams et al., 2020), (Figure 3e and

Supplementary Figure 7a).

No differences in the relative proportions of any of the myeloid populations were

evident between the two PCLD phenotypes (Figure 3f). Very few gene expression

differences were detected between the two phenotypes by pseudobulk analysis of

macrophage or monocyte subsets (Supplementary Table 2). Similar to the analysis of

the full dataset stratified by broad cell type, re-clustering macrophages to identify more

discrete sub-populations did not reveal transcriptomic differences between

inflammatory and fibrotic PCLD.

Single-cell differential gene expression analysis revealed weak enrichment for

immune response and cellular metabolism pathways in both groups (Supplementary

Figure 7b,c). Minor enrichment for TGFβ-mediated signalling was evident for genes

expressed at higher levels in AM, Inflam-AM and *FCN1*-Mono in inflammatory PCLD

(Supplementary Figure 7b). Proinflammatory cytokines, T cell activation factors, SPP1

and TGFβ were identified as statistically enriched upstream regulators of differentially

expressed genes in both monocyte populations in inflammatory PCLD

(Supplementary Figure 8a,b,d,e). However, as for analysis at the level of broad cell

types and refined T cell subsets, there was considerable overlap between molecules

predicted to drive gene expression differences in each PCLD phenotype

(Supplementary Figure 8c,f), suggesting that between group differential gene

expression in this analysis did not represent differential biology between radiological

patterns of disease.

Highly related TCRs indicate antigen-specific immune responses in PCLD

To further evaluate T cell responses in PCLD we undertook single-cell TCR

sequencing (scTCRseq) and compared the TCR repertoire in each radiological

phenotype. We successfully obtained scTCRseq data for five fibrotic and three

inflammatory cases. Increased T cell abundance in inflammatory PCLD may reflect

increased numbers of unique T cell clones or increased expansion of individual clones.

Expanded clonotypes identified by being present with a frequency of greater than one,

were evident within the three major T cell subsets in both inflammatory and fibrotic

PCLD (Figure 4a). A greater proportion of CD4 TCM clones were expanded in the

inflammatory phenotype, consistent with our observation of the higher abundance of

this subset in this group. However, the proportion of expanded CD8 TEM and Treg

clones was similar in both phenotypes (Figure 4b).

As T cell clonal expansion was evident in both PCLD phenotypes, we next sought to

identify related TCRs for each group based on the similarity of their antigen specificity-

determining complementarity determining region (CDR)3 amino acid sequences, on

the premise that clusters of related TCRs recognize similar epitopes (details of the

analysis are provided in the methods). We hypothesized that the inflammatory cases

would exhibit more clustering than the fibrotic cases, given the trend towards a greater

proportion of expanded CD4 TCM clones and increased abundance of both CD4 TCM

and CD8 TEM in the inflammatory group. However, high levels of clustering were

evident in both inflammatory and fibrotic PCLD. In benchmarking, this level of

clustering was similar to that observed for expanded peripheral blood TCR clones

detected following non-severe SARS-CoV-2 infection, and exceeded that in non-

expanded TCRs from non-infected individuals from the same cohort (Chandran et al.,

2022; Milighetti et al., 2023) (Figure 4c,d). In both radiological groups of PCLD the

vast majority of clusters contained TCRs from multiple donors (Figure 4e) but there

was minimal sharing of identical CDR3 sequences between different individuals

(Supplementary Table 3). As a further comparison of inflammatory and fibrotic PCLD

T cell repertoires we clustered CDR3 amino acid sequences from both groups

together. Strikingly, most clusters contained TCRs from both inflammatory and fibrotic

samples and multiple donors, suggesting the presence of T cell clones that recognize

similar antigens across both phenotypes. A few small clusters composed uniquely of

either inflammatory or fibrotic PCLD TCRs were evident, indicative of subtle

differences between the two repertoires (Figure 4f).

The high level of relatedness between TCRs in PCLD is suggestive of antigen-specific

immune responses. We therefore sought to determine whether these repertoires were

enriched for T cells specific for SARS-CoV-2 by comparison to other common viruses.

Of the SARS-CoV-2-reactive TCRs identified in the VDJdb database, six were present

in TCR data from inflammatory PCLD and eight in fibrotic PCLD. None were identified

in equivalent sized healthy peripheral blood repertoires. However, fewer SARS-CoV-

2-specific-TCRs were detected than Epstein-Barr virus (EBV)-specific or

cytomegalovirus (CMV)-specific sequences, indicating no enrichment for SARS-CoV-

2-specific T cells at the site of disease. There was no enrichment for SARS-CoV-2-

reactive or EBV-reactive TCRs in inflammatory compared to fibrotic PCLD. However,

CMV-specific TCRs were significantly enriched in the fibrotic group (Figure 4g). TCRs

found in clusters composed uniquely of either PCLD phenotype were not enriched for

known virus reactive-sequences (Supplementary Table 4).

DISCUSSION

We report the first comparative molecular analysis of cells sampled by bronchoalveolar

lavage from patients displaying either predominantly inflammatory or fibrotic

pulmonary radiological sequelae following COVID-19. The bronchoalveolar

environment of inflammatory PCLD was characterised by significantly increased

abundance of CD4 central memory and CD8 effector memory T cells compared to

fibrotic PCLD. Clustering of similar TCRs from different donors, far exceeding that

observed in healthy peripheral blood, was evident in both radiological phenotypes,

suggestive of an antigen-specific immune response localised to the lung. The

transcriptomes of post-COVID radiological inflammation and fibrosis were highly

similar for all bronchoalveolar cell types, dominated by cellular processes involved in

inflammatory and immune responses. We found no robust evidence of enhanced

activity of tissue damage or wound repair pathways in those with fibrotic radiological

changes. Although many cell type-specific differentially expressed genes were

identified between the two radiological phenotypes by single-cell methods, there were

no systematic differences in enriched biological pathways or their upstream regulators

among these differentially expressed genes. Furthermore, almost no differences in

gene expression between the fibrotic and the inflammatory groups were detected if

gene expression within cell types was aggregated by donor before differential analysis

(Squair et al., 2021). Our data lead us to propose that the two radiological phenotypes

represent distinct manifestations of a similar pathological process.

T cell infiltration has been a consistent finding in recent studies which have examined

the post-COVID-19 airspaces; almost exclusively within 3-6 months of the acute insult,

when radiological inflammation is more common than fibrosis (Cheon et al., 2021;

Gagiannis et al., 2023; Ravaglia et al., 2022; Vijayakumar et al., 2022). The cellular

proportions of our fibrotic PCLD samples, harvested at 9-12 months after acute illness,

were akin to those reported in BAL samples from healthy individuals, with

macrophages comprising greater than 80% and lymphocytes less than 15% of cells

(Mould et al., 2021; The BAL Cooperative Group Steering Committee, 1990). This is

in keeping with the reported repopulation of the airspaces by AM in the later stages of

COVID-19 acute respiratory distress syndrome (ARDS) (Wendisch et al., 2021).

Minimal data currently available for longitudinal samples obtained at approximately

one year post-infection also suggest a trajectory of gradual normalization of molecular

abnormalities and airspace cellular composition (Vijayakumar et al., 2022).

Nonetheless there is considerable interest in therapeutic intervention to expedite

resolution of subacute inflammation, to prevent progression to fibrosis with

concomitant irreversible tissue damage in susceptible individuals. Our findings

suggest therapies which target T cells, rather than anti-fibrotic agents could be

beneficial in PCLD, particularly in those with radiological inflammation. In support of

this premise, one small uncontrolled clinical study demonstrated improvement in

clinical symptoms, physiological parameters and radiological abnormalities, following

three weeks of corticosteroid treatment instituted approximately three months post-

COVID-19 (Myall et al., 2021).

The bronchoalveolar TCR repertoire from both PCLD phenotypes exhibited high levels

of relatedness, suggestive of antigen-specific immune responses. In addition, the high

proportion of clusters containing TCRs from multiple donors suggests immune

responses against similar antigens, despite almost no sharing of identical TCR

sequences between different individuals. Aberrant immune responses to persistent

reservoirs of virus have been posited as drivers of post-acute sequelae of SARS-CoV-

2 infection (Cheung et al., 2022; Merad et al., 2022; Stein et al., 2022). However, even

including all detected TCRs, to offset the inherent sparsity of single-cell data, there

was no enrichment for known SARS-CoV-2-specific T cell clones compared to TCRs

specific for other common viruses. Hence, based on the current compendium of

SARS-CoV-2-reactive TCRs (Bagaev et al., 2020), which may not be comprehensive,

there was no evidence for viral persistence at the site of disease in our cohort. A more

plausible hypothesis, given reports of cross-reactivity between SARS-CoV-2 and

human antigens (Nunez-Castilla et al., 2022; Vojdani and Kharrazian, 2020), is that

the PCLD TCR repertoire is directed against as yet unknown respiratory autoantigens.

Identifying the antigenic targets of the PCLD T cell repertoire may present

opportunities for more specific therapeutic interventions.

Pro-fibrotic macrophages have been implicated in the pathogenesis of severe COVID-

19 ARDS, which has been associated with rapid onset pulmonary fibrosis, which

improves over time (Wendisch et al., 2021). Minimal interstitial fibrosis and the

presence of pro-fibrotic macrophages have also been reported in transbronchial lung

biopsies from a subset of individuals sampled at least 12 weeks after mild COVID-19

(Gagiannis et al., 2023). However, there was no difference between the frequency at

which mild fibrotic features were detected in the PCLD group and pre-pandemic

autopsy samples from individuals who had died of non-respiratory causes (Gagiannis

et al., 2023). In our study, which encompassed a broad range of severity of acute

disease, including several individuals with COVID-19 ARDS, the phenotype of myeloid

cells in both radiological groups was consistent with the spectrum of macrophages

and monocytes found in healthy airspaces (Mould et al., 2021); with no convincing

evidence for exaggerated activity of pro-fibrogenic pathways. The heterogeneity of

disease phenotype and longer time interval after acute illness at which our cohort were

sampled may account for this discrepancy. Of note, CMV-specific T cell clones were

enriched in individuals with fibrotic PCLD, consistent with the repeated association of

CMV with pulmonary fibrosis (Moore and Moore, 2015). However, this observation is

of uncertain significance, given the lack of existing evidence for a direct role for CMV

in causing human pulmonary fibrosis (Moore and Moore, 2015).

Our study has some limitations. We acknowledge a small sample size, heterogeneous

patient cohort, and lack of specimens for histological correlation and orthogonal

validation of our single-cell data. Our findings provide early mechanistic insights, are

hypothesis-generating and will require further validation in larger cohorts. Those with

fibrotic radiological appearances were sampled later after acute disease than those

with radiological inflammation. Ideally, we would have more closely matched the

interval after acute COVID-19 at which both groups were sampled. However, the

introduction of dexamethasone treatment early in the second wave of the pandemic

was coincident with reduced numbers of individuals with persistent respiratory

symptoms and radiological abnormalities. Consequently, we extended the interval

after acute illness within which individuals were eligible for sampling. Since our aim

was to evaluate whether single-cell profiling of the bronchoalveolar environment of

individuals with inflammatory and fibrotic radiological patterns of PCLD at the time of

sampling would reveal different immunopathogenic mechanisms for these

phenotypes, we believe our approach remains valid. It also provided invaluable

opportunities to assess respiratory tract samples from the later stages of PCLD which

have received minimal attention to date. This was a cross-sectional evaluation of

bronchoalveolar immune cells, which did not allow assessment of the temporal

evolution of the immune response in PCLD within individuals. Future studies

encompassing longitudinal monitoring of the bronchoalveolar environment might

provide important insights into the molecular mechanisms driving resolution and

whether this trajectory is a universal phenomenon for both inflammation and fibrosis

following COVID-19. Augmented neutrophil-associated immune signatures have been

described in plasma and nasal samples in individuals with post-COVID pulmonary

sequelae, however, neutrophils were not detected in our samples, possibly due to the

Chromium 10x Genomics sample processing conditions used at the time of our

analysis (George et al., 2022). Finally, due to technical limitations because of the low

numbers of T cells present in BAL samples, we were unable to obtain TCR data for

two inflammatory cases. Nonetheless, our data provide strong support for the notion

that the TCR repertoire of PCLD reflects antigen-directed immune responses.

Our observations that inflammatory PCLD is characterised by airway T cell infiltration

and that antigen-specific T cell responses are evident in both radiological phenotypes,

highlight opportunities for early intervention with therapies targeting T cells.

Understanding the timing and duration of intervention, stratification of those at high

risk of irreversible tissue damage and the potential use of more targeted T cell

immunomodulators all merit further investigation.

METHODS

Ethics statement

The study was approved by the North London Research Ethics Committee

(13/LO/0900). Written informed consent was obtained from all participants. Subject

identifiers were not known to anyone outside the research group.

Study design and eligibility

Immune cells from the site of disease were obtained from adults (≥18 years)

undergoing bronchoscopy for clinical investigation of persistent respiratory symptoms

and CT abnormalities consistent with pulmonary inflammation (n=5) or fibrosis (n=5)

at least 12 weeks after acute COVID-19, confirmed by a positive SARS-CoV-2

antibody or polymerase chain reaction (PCR) test. PCLD was defined in this cohort

based on the following criteria: 1) new, persistent respiratory symptoms following

SARS-CoV-2 infection at least 12 weeks previously, 2) post-COVID-19 residual lung

abnormalities with more than 10% lung involvement on CT and 3) breathlessness in

keeping with the CT changes and not explained by other causes. Thoracic CT scans

were classified as predominantly inflammatory or fibrotic by consensus opinion of the

ILD multi-disciplinary team, which included thoracic radiologists with ILD expertise.

Radiological inflammation was defined as consolidation or ground glass opacities

without reticulation or parenchymal distortion and fibrosis defined as reticulation or

traction bronchiectasis. Individuals with evidence of ILD prior to COVID-19, those with

coincident malignancy, human immunodeficiency virus infection, bacterial, viral or

fungal respiratory tract infection, taking immunomodulatory therapy, or unable to give

informed consent were excluded.

Isolation of bronchoalveolar cells

Flexible fibreoptic bronchoscopy was used to obtain BAL samples by instillation of

180-240 ml of warmed normal saline into a lung segment affected by the predominant

radiological abnormality. Aspirated BAL fluid was cooled to 4°C and filtered through a

cell strainer to remove particulate debris before centrifugation. After removal of the

supernatant, cells were resuspended in PBS. Cell count and viability were determined

by Trypan blue staining and erythrocytes removed where indicated, using ammonium-

chloride-potassium red cell lysis buffer. Cells were resuspended at 2 x10^6 per ml for

immediate downstream processing.

scRNAseq and scTCRseq library preparation and sequencing

20,000 cells per sample were loaded on to the Chromium controller (10x Genomics)

to generate single-cell gel beads in emulsion (GEMs). Single-cell partitioning, reverse

transcription, cDNA amplification and library construction were performed using the

Chromium Single-cell 5' Reagent kits v1.1 and v2 (10x Genomics) according to the

manufacturer's instructions. T cell receptor (TCR) V(D)J segments were enriched from

amplified cDNA using Chromium Single-Cell V(D)J Enrichment kits v1.1 and v2 (10x

Genomics) per the manufacturer's protocol. Libraries were quality checked and

quantified using the High Sensitivity DNA kit and 4200 TapeStation (Agilent).

Sequencing was performed in paired end mode with SP100, P2 and P3 flow cells (100

cycles) using NovaSeq 6000 and NextSeq 2000 systems (Illumina).

scRNAseq data analysis

Cell Ranger

Raw sequencing files were demultiplexed using BCL Convert v3.7.5 (Illumina) or Cell

Ranger version 6.1.1 using the "mkfastq" script. Transcript alignment and quantitation

against the GRCh38 human genome assembly was performed using Cell Ranger

"multi" for samples with gene expression and T cell VDJ data or Cell Ranger "count"

for samples with gene expression data only.

Quality control

Initial processing of Cell Ranger output data was performed using Seurat v4.1.0 in R

4.1.1 (Stuart et al., 2019). Cell Ranger output files were loaded using the "Read10x"

function. Low quality cells with less than 200 or more than 6000 unique features or

more than 10% mitochondrial genes were removed; 57,712 cells were retained for

downstream analysis.

Normalization, feature selection and integration

For each sample data were normalized and highly variable genes selected before

integration to remove donor-specific batch effects, using the following Seurat functions

implemented with default parameters; NormalizeData (normalization.method =

"LogNormalize), FindVariableFeatures (selection.method = "vst", nfeatures = 2000),

IntegrateData (anchorset = immune.anchors).

Dimensional reduction, clustering and annotation

Data were then scaled using the Seurat ScaleData function and dimensional reduction

achieved by principal component analysis (PCA) of the most variable genes using

RunPCA. The first 25 principal components (PCs) were used to generate the Uniform

Manifold Approximation and Projection (UMAP) for two-dimensional visualization of

the cells (RunUMAP) and for nearest neighbor graph construction (FindNeighbors)

and Louvain clustering (FindClusters) using a resolution of 0.8. This clustering

resolution was selected on the basis that it successfully partitioned single-cell

transcriptomes into the broad cell types expected to be present in BAL. Automatic cell

type annotation of clusters was performed with the Semi-supervised Category

Identification and Assignment (SCINA) R package using gene signatures from the

Azimuth   human   lung   v1   reference

(https://azimuth.hubmapconsortium.org/references/#Human-Lungv1) (Travaglini et

al., 2020; Zhang et al., 2019). Additional manual annotation of dendritic cells and B

cells was performed using literature-based markers (Cheng et al., 2021; Glass et al.,

2020; Villani et al., 2017). A population with low numbers of genes, which could not be

annotated by automatic or manual methods and likely represents empty droplets

containing ambient RNA, was removed after clustering. To validate our clustering and

annotation strategy, we visualized the expression of canonical or published marker

genes for each cell type using a dot plot (Adams et al., 2020; Cheng et al., 2021; David

et al., 2021; Davies et al., 2013; Davis and Wypych, 2021; Gardell and Parker, 2017;

Glass et al., 2020; Murray and Wynn, 2011; Tsyklauri et al., 2023; van Aalderen et al.,

2021; Villani et al., 2017).

T cell and macrophage re-clustering

For separate analyses of T cells only and macrophages only, cells in the relevant

clusters were subsetted and normalization, variable feature selection, integration, data

scaling, PCA, UMAP generation and Louvain clustering repeated. The first 25 PCs

were used for data integration and clustering for both macrophages and T cells. The

k.weight parameter was reduced to 70 for the T cell integration step in order to take

account of the low number of cells in sample 12. Resolution 0.4 was used for re-

clustering T cells and resolution 0.7 for re-clustering macrophages. T cell subsets were

annotated using SCINA with Azimuth human PBMC reference marker genes

https://azimuth.hubmapconsortium.org/references/#Human-PBMC and additional

published CD4 T cell signatures (Cano-Gamez et al., 2020; Zhang et al., 2019).

Macrophages were annotated using SCINA with Azimuth human lung v1 reference

marker genes and additional signatures derived from published literature (Mould et al.,

2021; Travaglini et al., 2020; Wendisch et al., 2021; Zhang et al., 2019).

Calculation of gene module scores

The Seurat function AddModuleScore was used to calculate enrichment of a cyclin D1

(CCND1) regulated module representing the cellular proliferation response (Chandran

et al., 2022) and a profibrotic macrophage gene module derived from idiopathic

pulmonary fibrosis (Adams et al., 2020). Module scores represent the average

expression of gene signatures of interest with subtraction of the average expression

of control gene sets randomly selected from each expression bin which contains a

module gene.

Differential gene expression and differential cell type abundance analysis

For comparison of gene expression in individual cells (single-cell method) the scran R

package findMarkers function was implemented using the following settings: test.type

= "wilcox", direction = ''up'', pval.type = "all", lfc = 0. For identification of cell type

(cluster) marker genes, sample was included as a blocking factor. Genes with an

adjusted p-value <0.05 were considered significantly differentially expressed. For

comparison of gene expression at cell type level (pseudobulk method) the scuttle R

package aggregateAcrossCells function was used to aggregate counts for each cell

type within each sample to create "pseudobulks" before statistical analysis was

performed. Differentially expressed genes were identified using the scran

pseudoBulkDGE function, implementing the edgeR negative binomial generalized

linear model with quasi-likelihood F test (GLM-QLF) (Robinson et al., 2010). Genes

with an adjusted p-value <0.05 were considered significant. Differences in cell type

abundance between inflammatory and fibrotic PCLD were identified using the edgeR

GLM-QLF test implemented by scran. Cell types with an adjusted p-value <0.05 were

considered differentially abundant.

Pathway enrichment analysis

The biological pathways represented by differentially expressed genes were identified

by Reactome pathway enrichment analysis using XGR as previously described (Fang

et al., 2016; Turner et al., 2021). For visualization, 15 pathway groups were identified

by hierarchical clustering of Jaccard indices to quantify similarity between the gene

compositions of each pathway. For each group the pathway term with the largest

number of annotated genes was then selected as representative of the enriched

biology.

Upstream regulator analysis

Ingenuity Pathway Analysis (Qiagen) was used to identify upstream transcriptional

regulation of differentially expressed genes. This analysis was restricted to molecules

annotated with the following functions: cytokine, growth factor, transmembrane

receptor, kinase and transcriptional regulator, representing the canonical components

of pathways which execute transcriptional reprogramming in immune and tissue repair

responses. Enriched molecules with an adjusted p-value <0.05 were considered

statistically significant. Area-proportional Venn diagrams visualizing the overlap

between molecules predicted to regulate cell type-specific differentially expressed

genes in inflammatory PCLD and fibrotic PCLD were generated using BioVenn

(Hulsen et al., 2008).

TCR quantitation and CDR3 clustering

TCR sequences were assembled by the Cell Ranger multi pipeline (v6.1.1). For single-

cell TCR analysis, TCR clonotype abundance information was imported directly from

Cell Ranger "filtered_contig_annotations" output files, where clonotype identity was

determined as cells with identical V(D)J and CDR3 sequences. Clonotypes were

assigned to single cells using index barcodes. TCRs found more than once were

defined as expanded. Density plots were calculated using the UMAP coordinates of

every expanded cell with a detectable TCR using geom_density_2d from the ggplot2

package.

For clustering analysis of each PCLD phenotype individually, all detected alpha and

beta chain sequences in the inflammatory samples were included, to take account of

the sparsity of single-cell data. Including larger numbers of TCR sequences leads to

more clustering (Madi et al., 2017); fibrotic PCLD and control group TCR sequences

were therefore subsampled to match the number of sequences in the inflammatory

PCLD group, which contained the smallest repertoire. We included expanded

peripheral blood TCRs from individuals with non-severe SARS-CoV-2 infection as a

positive control dataset known to exhibit high levels of clustering and non-expanded

TCRs randomly selected from uninfected individuals from this same cohort, as a

negative control dataset, not expected to cluster highly (Chandran et al., 2022;

Milighetti et al., 2023). For the combined analysis of both PCLD phenotypes all

detected CDR3 sequences were included. TCR clustering was performed as

previously described (Joshi et al., 2019). Briefly, CDR3 amino acid sequences were

deconstructed into overlapping series of contiguous triplets. Pairwise similarity

between two CDR3s was calculated as the normalized string (triplet) kernel using the

Kernlab R package (Karatzoglou et al., 2004). The resulting TCR similarity matrix was

converted into a network diagram in which CDR3s with a pairwise similarity above a

designated threshold were connected by an edge using the iGraph R package (Csardi

and Nepusz, 2006). We visualized thresholds at which PCLD TCRs exhibited the

largest increase in the percentage of TCRs clustering compared to negative control

TCR data for clustering of PCLD groups individually. For combined clustering of

inflammatory and fibrotic PCLD we visualized thresholds at which the largest clusters

composed uniquely of one phenotype were present.

Virus specific TCR enrichment analysis

TCRs annotated for SARS-CoV-2, CMV and EBV were obtained from the VDJdb

database (Bagaev et al., 2020) (https://vdjdb.cdr3.net/), accessed on 1st November

2021. The number of annotated sequences for each virus in VDJdb either matching

or not matching TCRs detected in inflammatory and fibrotic PCLD or the negative

controls was used to calculate the odds ratio (Fisher's exact test) for enrichment of

virus-specific TCRs in each group.

Data availability

scRNAseq and scTCRseq data will be available in the Gene Expression Omnibus

(GEO) database at the time of peer-reviewed publication of the manuscript under

accession number GSE228236.

ACKNOWLEDGEMENTS

We thank Dr Arjun Nair for oversight of the ILD MDT discussions to classify radiological

changes as predominantly inflammatory or fibrotic and for identification of lung

segments to be targeted for sampling by BAL.

REFERENCES

Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, Chu SG, Raby
BA, Deluliis G, Januszyk M, Duan Q, Arnett HA, Siddiqui A, Washko GR,
Homer R, Yan X, Rosas IO, Kaminski N. 2020. Single-cell RNA-seq reveals
ectopic and aberrant lung-resident cell populations in idiopathic pulmonary
fibrosis. *Sci Adv* **6**:eaba1983. doi:10.1126/sciadv.aba1983

Auffray C, Sieweke MH, Geissmann F. 2009. Blood monocytes: development,
heterogeneity, and relationship with dendritic cells. *Annu Rev Immunol*
27:669–692. doi:10.1146/annurev.immunol.021908.132557

Bagaev DV, Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G, Greenshields-
Watson A, Attaf M, Egorov ES, Zvyagin IV, Babel N, Cole DK, Godkin AJ,
Sewell AK, Kesmir C, Chudakov DM, Luciani F, Shugay M. 2020. VDJdb in
2019: database extension, new analysis infrastructure and a T-cell receptor
motif compendium. *Nucleic Acids Res* **48**:D1057–D1062.
doi:10.1093/nar/gkz874

Cano-Gamez E, Soskic B, Roumeliotis TI, So E, Smyth DJ, Baldrighi M, Willé D,
Nakic N, Esparza-Gordillo J, Larminie CGC, Bronson PG, Tough DF, Rowan
WC, Choudhary JS, Trynka G. 2020. Single-cell transcriptomics identifies an
effectorness gradient shaping the response of CD4+ T cells to cytokines. *Nat*
Commun **11**:1801. doi:10.1038/s41467-020-15543-y

Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, Burton
AR, Guerra-Assunção JA, Woolston A, Ronel T, Pade C, Gibbons JM, Sanz-
Magallon Duque De Estrada B, Robert de Massy M, Whelan M, Semper A,
Brooks T, Altmann DM, Boyton RJ, McKnight Á, Captur G, Manisty C, Treibel
TA, Moon JC, Tomlinson GS, Maini MK, Chain BM, Noursadeghi M,
COVIDsortium Investigators. 2022. Rapid synchronous type 1 IFN and virus-
specific T cell responses characterize first wave non-severe SARS-CoV-2
infections. *Cell Rep Med* **3**:100557. doi:10.1016/j.xcrm.2022.100557

Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Yu, Qin S, Zhang L, Ouyang H, Du P,

Jiang L, Zhang B, Yang Yue, Wang X, Ren X, Bei J-X, Hu X, Bu Z, Ji J,
Zhang Z. 2021. A pan-cancer single-cell transcriptional atlas of tumor
infiltrating myeloid cells. *Cell* **184**:792-809.e23. doi:10.1016/j.cell.2021.01.010

Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, Wang Z, Wei X, Tang J, Li
Y, Marlow H, Hughes S, Hammel L, Cox TM, Goddery E, Ayasoufi K,
Weiskopf D, Boonyaratanakornkit J, Dong H, Li H, Chakraborty R, Johnson
AJ, Edell E, Taylor JJ, Kaplan MH, Sette A, Bartholmai BJ, Kern R, Vassallo
R, Sun J. 2021. Immune signatures underlying post-acute COVID-19 lung
sequelae. *Sci Immunol* **6**:eabk1741. doi:10.1126/sciimmunol.abk1741

Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY,
Chen EX, Nerurkar SN, Loong S, Cheow PC, Chan CY, Koh YX, Tan TT,
Kalimuddin S, Tai WMD, Ng JL, Low JG-H, Yeong J, Lim KH. 2022. Residual
SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five
recovered patients with COVID-19. *Gut* **71**:226–229. doi:10.1136/gutjnl-2021-
324280

Csardi G, Nepusz T. 2006. The igraph software package for complex network
research. *Complex Syst* **1695**:1–9.

David G, Willem C, Legrand N, Djaoud Z, Mérieau P, Walencik A, Guillaume T,
Gagne K, Chevallier P, Retière C. 2021. Deciphering the biology of KIR2DL3+
T lymphocytes that are associated to relapse in haploidentical HSCT. *Sci Rep*
11:15782. doi:10.1038/s41598-021-95245-7

Davies LC, Jenkins SJ, Allen JE, Taylor PR. 2013. Tissue-resident macrophages.
Nat Immunol **14**:986–995. doi:10.1038/ni.2705

Davis JD, Wypych TP. 2021. Cellular and functional heterogeneity of the airway
epithelium. *Mucosal Immunol* **14**:978–990. doi:10.1038/s41385-020-00370-7

Fabbri L, Moss S, Khan FA, Chi W, Xia J, Robinson K, Smyth AR, Jenkins G,
Stewart I. 2023. Parenchymal lung abnormalities following hospitalisation for
COVID-19 and viral pneumonitis: a systematic review and meta-analysis.
Thorax **78**:191–201. doi:10.1136/thoraxjnl-2021-218275

Fang H, Knezevic B, Burnham KL, Knight JC. 2016. XGR software for enhanced
interpretation of genomic summary data, illustrated by application to
immunological traits. *Genome Med* **8**:129. doi:10.1186/s13073-016-0384-y

Gagiannis D, Hackenbroch C, Bloch W, Zech F, Kirchhoff F, Djudjaj S, von Stillfried
S, Bülow R, Boor P, Steinestel K. 2023. Clinical, Imaging, and
Histopathological Features of Pulmonary Sequelae Following Mild COVID-19.
Am J Respir Crit Care Med. doi:10.1164/rccm.202302-0285LE

Gardell JL, Parker DC. 2017. CD40L is transferred to antigen-presenting B cells
during delivery of T-cell help. *Eur J Immunol* **47**:41–50.
doi:10.1002/eji.201646504

George PM, Reed A, Desai SR, Devaraj A, Faiez TS, Laverty S, Kanwal A, Esneau
C, Liu MKC, Kamal F, Man WD-C, Kaul S, Singh S, Lamb G, Faizi FK,
Schuliga M, Read J, Burgoyne T, Pinto AL, Micallef J, Bauwens E, Candiracci
J, Bougoussa M, Herzog M, Raman L, Ahmetaj-Shala B, Turville S, Aggarwal
A, Farne HA, Dalla Pria A, Aswani AD, Patella F, Borek WE, Mitchell JA,
Bartlett NW, Dokal A, Xu X-N, Kelleher P, Shah A, Singanayagam A. 2022. A
persistent neutrophil-associated immune signature characterizes post-COVID-

19 pulmonary sequelae. *Sci Transl Med* **14**:eabo5795.
doi:10.1126/scitranslmed.abo5795

Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, Borges L,
Glass MC, Wagar LE, Davis MM, Bendall SC. 2020. An Integrated Multi-omic
Single-Cell Atlas of Human B Cell Identity. *Immunity* **53**:217-232.e5.
doi:10.1016/j.immuni.2020.06.013

Hulsen T, de Vlieg J, Alkema W. 2008. BioVenn - a web application for the
comparison and visualization of biological lists using area-proportional Venn
diagrams. *BMC Genomics* **9**:488. doi:10.1186/1471-2164-9-488

Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E,
Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V,
Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Sunderland MW, Jamal-
Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-
Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS,
McGranahan N, Swanton C, TRACERx consortium, Quezada SA, Chain B.
2019. Spatial heterogeneity of the T cell receptor repertoire reflects the
mutational landscape in lung cancer. *Nat Med* **25**:1549–1559.
doi:10.1038/s41591-019-0592-2

Karatzoglou A, Smola A, Hornik K, Zeileis A. 2004. kernlab - An S4 Package for
Kernel Methods in R. *J Stat Softw* **11**:1–20. doi:10.18637/jss.v011.i09

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L,
Amit I, Zhang S, Zhang Z. 2020. Single-cell landscape of bronchoalveolar
immune cells in patients with COVID-19. *Nat Med* **26**:842–844.
doi:10.1038/s41591-020-0901-9

Madi A, Poran A, Shifrut E, Reich-Zeliger S, Greenstein E, Zaretsky I, Arnon T,
Laethem FV, Singer A, Lu J, Sun PD, Cohen IR, Friedman N. 2017. T cell
receptor repertoires of mice and humans are clustered in similarity networks
around conserved public CDR3 sequences. *eLife* **6**:e22057.
doi:10.7554/eLife.22057

Mehta P, Rosas IO, Singer M. 2022. Understanding post-COVID-19 interstitial lung
disease (ILD): a new fibroinflammatory disease entity. *Intensive Care Med*
48:1803–1806. doi:10.1007/s00134-022-06877-w

Merad M, Blish CA, Sallusto F, Iwasaki A. 2022. The immunology and
immunopathology of COVID-19. *Science* **375**:1122–1127.
doi:10.1126/science.abm8108

Milighetti M, Peng Y, Tan C, Mark M, Nageswaran G, Byrne S, Ronel T, Peacock T,
Mayer A, Chandran A, Rosenheim J, Whelan M, Yao X, Liu G, Felce SL,
Dong T, Mentzer AJ, Knight JC, Balloux F, Greenstein E, Reich-Zeliger S,
Pade C, Gibbons JM, Semper A, Brooks T, Otter A, Altmann DM, Boyton RJ,
Maini MK, McKnight A, Manisty C, Treibel TA, Moon JC, Noursadeghi M,
Chain B. 2023. Large clones of pre-existing T cells drive early immunity
against SARS-COV-2 and LCMV infection. *iScience* **26**.
doi:10.1016/j.isci.2023.106937

Moore BB, Moore TA. 2015. Viruses in Idiopathic Pulmonary Fibrosis. Etiology and
Exacerbation. *Ann Am Thorac Soc* **12 Suppl 2**:S186-192.
doi:10.1513/AnnalsATS.201502-088AW

Mould KJ, Moore CM, McManus SA, McCubbrey AL, McClendon JD, Griesmer CL,
Henson PM, Janssen WJ. 2021. Airspace Macrophages and Monocytes Exist
in Transcriptionally Distinct Subsets in Healthy Adults. *Am J Respir Crit Care*
Med **203**:946–956. doi:10.1164/rccm.202005-1989OC

Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage
subsets. *Nat Rev Immunol* **11**:723–737. doi:10.1038/nri3073

Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, Preston R,
Thillai M, Dewar A, Molyneaux PL, West AG. 2021. Persistent Post-COVID-19
Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.
Ann Am Thorac Soc **18**:799–806. doi:10.1513/AnnalsATS.202008-1002OC

Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, Ichiki M,
Momosaki S, Nakamura M, Fujimoto K, Fukuoka J, Shimizu S, Komohara Y,
Hoshino T. 2019. Elevation of pulmonary CD163 + and CD204 +
macrophages is associated with the clinical course of idiopathic pulmonary
fibrosis patients. *J Thorac Dis* **11**. doi:10.21037/jtd.2019.09.03

Nunez-Castilla J, Stebliankin V, Baral P, Balbin CA, Sobhan M, Cickovski T, Mondal
AM, Narasimhan G, Chapagain P, Mathee K, Siltberg-Liberles J. 2022.
Potential Autoimmunity Resulting from Molecular Mimicry between SARS-
CoV-2 Spike and Human Proteins. *Viruses* **14**:1415. doi:10.3390/v14071415

Ravaglia C, Doglioni C, Chilosi M, Piciucchi S, Dubini A, Rossi G, Pedica F, Puglisi
S, Donati L, Tomassetti S, Poletti V. 2022. Clinical, radiological and
pathological findings in patients with persistent lung disease following SARS-
CoV-2 infection. *Eur Respir J* **60**:2102411. doi:10.1183/13993003.02411-2021

Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. *Bioinforma*
Oxf Engl **26**:139–140. doi:10.1093/bioinformatics/btp616

Squair JW, Gautier M, Kathe C, Anderson MA, James ND, Hutson TH, Hudelle R,
Qaiser T, Matson KJE, Barraud Q, Levine AJ, La Manno G, Skinnider MA,
Courtine G. 2021. Confronting false discoveries in single-cell differential
expression. *Nat Commun* **12**:5692. doi:10.1038/s41467-021-25960-2

Stein SR, Ramelli SC, Grazioli A, Chung J-Y, Singh M, Yinda CK, Winkler CW, Sun
J, Dickey JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S,
Purcell M, Munster VJ, Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA,
Herr DL, Rabin J, Saharia KK, Madathil RJ, Tabatabai A, Soherwardi S,
McCurdy MT, NIH COVID-19 Autopsy Consortium, Peterson KE, Cohen JI, de
Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. 2022. SARS-CoV-2
infection and persistence in the human body and brain at autopsy. *Nature*
612:758–763. doi:10.1038/s41586-022-05542-y

Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Aslani S, Baillie
JK, Barratt SL, Beirne P, Bianchi SM, Blaikley JF, Chalmers JD, Chambers
RC, Chaudhuri N, Coleman C, Collier G, Denneny EK, Docherty A, Elneima
O, Evans RA, Fabbri L, Gibbons MA, Gleeson FV, Gooptu B, Greening NJ,
Guillen Guio B, Hall IP, Hanley NA, Harris V, Harrison EM, Heightman M,
Hillman TE, Horsley A, Houchen-Wolloff L, Jarrold I, Johnson SR, Jones MG,
Khan F, Lawson R, Leavy O, Lone N, Marks M, McAuley H, Mehta P, Parekh
D, Piper Hanley K, Platé M, Pearl J, Poinasamy K, Quint JK, Raman B,

Richardson M, Rivera-Ortega P, Saunders L, Saunders R, Semple MG,
Sereno M, Shikotra A, Simpson AJ, Singapuri A, Smith DJ, Spears M,
Spencer LG, Stanel S, Thickett D, Thompson AAR, Thorpe M, Walsh SL,
Walker S, Weatherley ND, Weeks M, Wild JM, Wootton DG, Brightling CE, Ho
L-P, Wain LV, Jenkins RG. 2022. Residual Lung Abnormalities Following
COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study.
Am J Respir Crit Care Med. doi:10.1164/rccm.202203-0564OC

Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y,
Stoeckius M, Smibert P, Satija R. 2019. Comprehensive Integration of Single-
Cell Data. *Cell* **177**:1888-1902.e21. doi:10.1016/j.cell.2019.05.031

The BAL Cooperative Group Steering Committee. 1990. Bronchoalveolar lavage
constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected
comparison groups. *Am Rev Respir Dis* **141**:S169-202.
doi:10.1164/ajrccm/141.5_Pt_2.S169

Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, Chang S, Conley
SD, Mori Y, Seita J, Berry GJ, Shrager JB, Metzger RJ, Kuo CS, Neff N,
Weissman IL, Quake SR, Krasnow MA. 2020. A molecular cell atlas of the
human lung from single-cell RNA sequencing. *Nature* **587**:619–625.
doi:10.1038/s41586-020-2922-4

Tsyklauri O, Chadimova T, Niederlova V, Kovarova J, Michalik J, Malatova I,
Janusova S, Ivashchenko O, Rossez H, Drobek A, Vecerova H, Galati V,
Kovar M, Stepanek O. 2023. Regulatory T cells suppress the formation of
potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2. *eLife*
12:e79342. doi:10.7554/eLife.79342

Turner CT, Brown J, Shaw E, Uddin I, Tsaliki E, Roe JK, Pollara G, Sun Y, Heather
JM, Lipman M, Chain B, Noursadeghi M. 2021. Persistent T Cell Repertoire
Perturbation and T Cell Activation in HIV After Long Term Treatment. *Front*
Immunol **12**:634489. doi:10.3389/fimmu.2021.634489

van Aalderen MC, van Lier RAW, Hombrink P. 2021. How to Reliably Define Human
CD8+ T-Cell Subsets: Markers Playing Tricks. *Cold Spring Harb Perspect Biol*
13:a037747. doi:10.1101/cshperspect.a037747

Vijayakumar B, Boustani K, Ogger PP, Papadaki A, Tonkin J, Orton CM, Ghai P,
Suveizdyte K, Hewitt RJ, Desai SR, Devaraj A, Snelgrove RJ, Molyneaux PL,
Garner JL, Peters JE, Shah PL, Lloyd CM, Harker JA. 2022. Immuno-
proteomic profiling reveals aberrant immune cell regulation in the airways of
individuals with ongoing post-COVID-19 respiratory disease. *Immunity*
55:542-556.e5. doi:10.1016/j.immuni.2022.01.017

Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M,
Butler A, Zheng S, Lazo S, Jardine L, Dixon D, Stephenson E, Nilsson E,
Grundberg I, McDonald D, Filby A, Li W, De Jager PL, Rozenblatt-Rosen O,
Lane AA, Haniffa M, Regev A, Hacohen N. 2017. Single-cell RNA-seq reveals
new types of human blood dendritic cells, monocytes, and progenitors.
Science **356**:eaah4573. doi:10.1126/science.aah4573

Vojdani A, Kharrazian D. 2020. Potential antigenic cross-reactivity between SARS-
CoV-2 and human tissue with a possible link to an increase in autoimmune
diseases. *Clin Immunol* **217**:108480. doi:10.1016/j.clim.2020.108480

768 Wauters E, Van Mol P, Garg AD, Jansen S, Van Herck Y, Vanderbeke L, Bassez A,
769    Boeckx B, Malengier-Devlies B, Timmerman A, Van Brussel T, Van Buyten T,
770    Schepers R, Heylen E, Dauwe D, Dooms C, Gunst J, Hermans G,
771    Meersseman P, Testelmans D, Yserbyt J, Tejpar S, De Wever W, Matthys P,
772    Neyts J, Wauters J, Qian J, Lambrechts D. 2021. Discriminating mild from
773    critical COVID-19 by innate and adaptive immune single-cell profiling of
774    bronchoalveolar lavages. *Cell Res* **31**:272–290. doi:10.1038/s41422-020-
775    00455-9

776 Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C,
777    Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL,
778    Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S,
779    Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K,
780    Conrad Claudia, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst
781    D, Deutsche COVID-19 OMICS Initiative (DeCOI), Hippenstiel S, Hocke A,
782    Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault
783    C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F,
784    Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE,
785    Luecken MD, Theis FJ, Conrad Christian, Wolff T, Boor P, Selbach M, Saliba
786    A-E, Sander LE. 2021. SARS-CoV-2 infection triggers profibrotic macrophage
787    responses and lung fibrosis. *Cell* **184**:6243-6261.e27.
788    doi:10.1016/j.cell.2021.11.033

789 Zhang Z, Luo D, Zhong X, Choi JH, Ma Y, Wang S, Mahrt E, Guo W, Stawiski EW,
790    Modrusan Z, Seshagiri S, Kapur P, Hon GC, Brugarolas J, Wang T. 2019.
791    SCINA: A Semi-Supervised Subtyping Algorithm of Single Cells and Bulk
792    Samples. *Genes* **10**:531. doi:10.3390/genes10070531

FIGURES

Figure 1. Higher abundance of bronchoalveolar T cells in inflammatory post-COVID-

19 lung disease (PCLD). **a** Representative computed tomography (CT) images for

each radiological phenotype. **b** Uniform manifold approximation and projection

(UMAP) embedding of 55,776 bronchoalveolar single-cell transcriptomes obtained

from five individuals with radiological features of pulmonary inflammation (33,553

cells) and five individuals with radiological features of pulmonary fibrosis (22,223 cells)

following COVID-19, split by PCLD phenotype, color coded by cell type. Cell type

annotation was achieved by assignment of Azimuth human lung reference gene

signatures using the SCINA R package and in the case of dendritic cells and B cells,

expression of literature-based markers. Prolif = proliferating cells, identified by their

high module score for a gene signature representing the cellular proliferation

response. **c** Cellular composition of each BAL sample defined by single-cell RNA

sequencing (scRNAseq). Color indicates cell type and bar height represents

proportion. **d** Dot plot visualization of the expression of independently established

marker genes for each cell type; "Mac" = macrophage. Dot size represents the

percentage of cells expressing the gene in each cell type, color shows the z-scores of

average log-normalized expression for each cell type compared to the entire data set.

e Comparison of the proportions of each cell type in inflammatory and fibrotic PCLD.

Horizontal lines indicate median, box limits the interquartile range and whiskers the 5th

to 95th percentiles, * = FDR<0.05.

Figure 2. Post-COVID-19 bronchoalveolar T cells are dominated by CD4 central memory and CD8 effector memory subsets. **a** UMAP embedding of 9196 transcriptomes of T cells identified in Figure 1**b**, colored by cell type. T cell subset annotation was based on assignment of Azimuth human PBMC reference marker gene signatures and additional published CD4 T cell signatures by the SCINA R package. **b** Relative proportions of each T cell subset in each subject, colors represent cell type. **c** Feature plots demonstrating the expression of marker genes for the three principal T cell subsets and NK cells, colored by scaled, log-normalized counts, projected on to the T cell UMAP. **d** Comparison of the proportions of T cell subsets found in all individuals in inflammatory and fibrotic post-COVID-19 lung disease (PCLD). Horizontal lines indicate median, box limits the interquartile range and whiskers the 5th to 95th percentiles.

Figure 3. Bronchoalveolar macrophage and monocyte subsets in post-COVID-19 lung

disease (PCLD). **a** UMAP embedding of 38,010 macrophage transcriptomes identified

in Figure 1**b**, colored by cell type. Myeloid populations were annotated by assignment

of Azimuth human lung reference marker genes and additional signatures derived from

published literature using the SCINA R package and by visualising expression of

canonical marker genes for some subsets. **b** Relative proportions of each myeloid

subset within each individual, colors represent cell type. **c** Expression of marker genes

for PCLD macrophage and monocyte populations, colored by scaled, log-normalized

counts, projected on to the myeloid cell UMAP. **d** Dot plot visualization of the

expression of selected marker genes for each macrophage and monocyte subset. Dot

size represents the percentage of cells expressing the gene in each myeloid subset,

color shows the z-scores of average log-normalized expression for each subset

compared to the entire data set. **e** Expression of a profibrotic macrophage gene

signature derived from idiopathic pulmonary fibrosis, calculated on a single-cell level,

colored by module score and projected on to the macrophage UMAP. **f** Comparison

of the proportions of bronchoalveolar myeloid populations in inflammatory and fibrotic

PCLD. Horizontal lines indicate median, box limits the interquartile range and whiskers

the 5th to 95th percentiles.

Figure 4. Highly similar T cell receptors (TCRs) characterize both inflammatory and

fibrotic post-COVID lung disease (PCLD). **a** T cell clonal expansion is visualized on

the T cell UMAP split by radiological PCLD phenotype. TCR sequences detected at a

frequency of greater than one are colored light blue and contour lines provide a 2D

representation of TCR density overlaid in red for inflammatory PCLD and blue for

fibrotic PCLD. **b** Comparison of the proportion of expanded TCR sequences, defined

as those detected at a frequency greater than one in the three largest T cell subsets

identified in Figure 2**a** in the two PCLD phenotypes. **c** Percentage of complementarity

determining region (CDR)3 alpha and beta chain amino acid sequences clustering and

number of clusters generated over a range of thresholds above which two TCRs are

considered similar, for inflammatory and fibrotic PCLD bronchoalveolar lavage (BAL)

samples, negative control PBMC samples not expected to cluster highly and positive

control PBMC samples known to cluster highly, analyzed separately. **d** Representative

network diagrams of TCR β chain clusters present in each group described in (**c**).

Nodes represent TCRs, related TCRs are connected by an edge and colors represent

the groups. **e** Network diagrams of related TCR β chains in each PCLD phenotype in

which nodes are colored by donor. **f** Network diagrams visualizing TCR β chain

clusters identified by combined analysis of the two PCLD phenotypes. Nodes are

colored by donor (right) or radiological phenotype and membership of clusters

composed of one or both PCLD groups (left), circular nodes represent inflammatory

PCLD and square nodes fibrotic PCLD. **g** Number of TCR sequences (α and β genes

combined) annotated for SARS-CoV-2, cytomegalovirus (CMV), and Epstein-Barr

virus (EBV) in VDJdb either detected or not detected in TCR sequences from

individuals with each PCLD phenotype and negative controls, giving the odds ratio

±95% confidence interval (Fisher's exact test) for enrichment of antigen-specific TCR

sequences in each instance.

TABLES

Table 1. Clinical and demographic information summary.

	Inflammatory N=5	Fibrotic N=5
Age		
Median (IQR)	62 (21.5)	59 (8.5)
Sex		
Male	2 (40%)	4 (80%)
Female	3 (60%)	1 (20%)
Ethnicity		
White	3 (60%)	3 (60%)
Asian	2 (40%)	2 (40%)
Body mass index (kg/m^2)		
Median (IQR)	31.8 (15.6)	27.3 (6.1)
Smoking Status		
Never	4 (80%)	2 (40%)
Former	1 (20%)	3 (60%)
COVID-19 wave		
1	2 (40%)	2 (40%)
2	3 (60%)	3 (60%)
Respiratory Support		
I&V†	2* (40%)	4 (80%)
CPAP‡	1 (20%)	0
HFNO‡	1 (20%)	1 (20%)
nil	1 (20%)	0
Treatment for COVID-19		
Steroid	3 (60%)	5 (100%)
Tocilizumab	1 (20%)	1 (20%)
Anti-viral	0	0
BAL		
Days post-acute COVID (median (IQR))	116 (50)	316 (50.5)

*One patient also received ECMO (extracorporeal membrane oxygenation); †I&V
Intubation and ventilation; ‡CPAP Continuous Positive Airways Pressure; ‡HFNO
High Flow Nasal Oxygen.

Support statement

PM is supported by a Medical Research Council (MRC)/GlaxoSmithKline

Experimental Medicine Initiative to Explore New Therapies network (EMINENT)

Clinical Research Training Fellowship. EKD is supported by Breathing Matters. MZN

is supported by a UK MRC Clinician Scientist Fellowship (MR/W00111X/1) and a

Rutherford Fund Fellowship allocated by the MRC UK Regenerative Medicine Platform

2 (MR/5005579/1). MN is supported by the Wellcome Trust (207511/Z/17/Z). GST is

supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). PM, EKD,

MP, JSB, MZN, MN, RCC, JCP and GST are also supported by NIHR Biomedical

Research Funding to UCL and UCLH.

Author contributions

GST, JCP, RCC and MZN conceived the study.

EKD, PM, KBW, MY, JCP and GST collected the data.

PM, EKD, KW, MY 10x Genomics platform.

BSMDDE, CTT, KF, MM, MZN, MP, JSB, BMC and MN provided resources or analysis

tools.

BSMDDE, KF and GST performed the computational data analysis with contributions

from AM, MM, BMC and MN.

PM, BSMDDE, EKD and GST prepared the manuscript draft.

All authors reviewed and contributed to the final manuscript.

COMPETING INTERESTS

All authors declare no competing interests.

39